Evofem Biosciences Enters Manufacturing Agreement for PHEXX

What Happened
Evofem Biosciences, Inc. announced on September 23, 2026 (8-K filing) that it entered into a Manufacturing Agreement dated September 17, 2026 with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited. Under the agreement, Zhaoke agreed to become a manufacturer and supplier of PHEXX® (lactic acid, citric acid, and potassium bitartrate). The filing includes the Manufacturing Agreement as Exhibit 10.1; certain confidential portions of that exhibit were omitted from the public filing.

Key Details

• Agreement date: September 17, 2026; 8-K filed: September 23, 2026.
• Product named: PHEXX® (lactic acid, citric acid, potassium bitartrate).
• Counterparties: Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited.
• The public filing does not disclose financial terms, volumes, pricing, or detailed commercial timelines; portions of Exhibit 10.1 are redacted as confidential ([***]).

Why It Matters
This agreement formally identifies a contract manufacturer/supplier for PHEXX, which is a key operational step if Evofem plans to produce or commercialize that product. For investors, a named manufacturer can affect supply chain readiness and timing for product availability. However, the filing does not provide financial or volume terms, so the potential revenue or cost impact of this arrangement is not disclosed in the 8-K.